Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dicerna Pharmaceutic (DRNA)

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,618,422
  • Shares Outstanding, K 77,734
  • Annual Sales, $ 164,310 K
  • Annual Income, $ -112,750 K
  • 60-Month Beta 0.99
  • Price/Sales 10.22
  • Price/Cash Flow N/A
  • Price/Book 14.70
Trade DRNA with:

Options Overview Details

View History
  • Implied Volatility 77.99%
  • Historical Volatility 39.91%
  • IV Percentile 79%
  • IV Rank 55.44%
  • IV High 99.66% on 08/17/21
  • IV Low 51.04% on 04/20/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 74
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,769
  • Open Int (30-Day) 4,542

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate 0.28
  • Low Estimate -0.97
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -41.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.94 +3.69%
on 08/27/21
22.61 -8.54%
on 09/09/21
+0.04 (+0.19%)
since 08/20/21
3-Month
19.48 +6.16%
on 08/20/21
40.14 -48.48%
on 07/20/21
-16.75 (-44.75%)
since 06/21/21
52-Week
17.76 +16.44%
on 10/01/20
40.14 -48.48%
on 07/20/21
+2.07 (+11.12%)
since 09/21/20

Most Recent Stories

More News
RNAi Technology Market Size, Share, Value, Competitive landscape, Industry outlook and Future Forecast till 2027

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy...

ALNY : 184.15 (+0.38%)
DRNA : 20.68 (-0.67%)
ARWR : 62.36 (-0.06%)
IONS : 36.28 (+0.25%)
ABUS : 4.37 (+1.86%)
BLT : 10.00 (+0.20%)
SLN.LN : 530.000 (-3.99%)
Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -203.92% and -68.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

DRNA : 20.68 (-0.67%)
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update

--- Announced U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for DCR-AUD for Alcohol Use Disorder -

DRNA : 20.68 (-0.67%)
Dicerna Reports Positive Top-Line Results From PHYOX(TM)2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

--- Nedosiran Was Generally Well Tolerated in PHYOX2 With a Safety Profile Similar to Previously Reported PHYOX Trial Results -

DRNA : 20.68 (-0.67%)
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will...

DRNA : 20.68 (-0.67%)
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder

--- Dicerna Expects to Initiate Phase 1 Clinical Trial of DCR-AUD in the Third Quarter of 2021 -

DRNA : 20.68 (-0.67%)
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced interim results from...

DRNA : 20.68 (-0.67%)
New Strong Sell Stocks for July 20th

AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.

BIDU : 156.71 (+1.43%)
DRNA : 20.68 (-0.67%)
RACE : 214.71 (+0.72%)
CBAY : 3.82 (-0.52%)
AEVA : 8.78 (+0.34%)
New Strong Sell Stocks for July 15th

ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021

ATEC : 14.04 (+1.23%)
AG : 12.20 (+2.18%)
DRNA : 20.68 (-0.67%)
AUPH : 22.64 (+8.27%)
PAX : 16.52 (-1.73%)
Stocks Mixed Amid Earnings Reports, Powell and PPI

Stocks Mixed Amid Earnings Reports, Powell and PPI

JOAN : 11.64 (+0.26%)
HROW : 9.82 (+3.81%)
DFH : 18.38 (-2.70%)
STKS : 10.76 (-2.89%)
DCT : 47.80 (-0.29%)
ABNB : 169.29 (+4.73%)
NVTA : 31.79 (+3.11%)
DRNA : 20.68 (-0.67%)
HAL : 19.48 (-0.61%)
C : 66.94 (-0.53%)
WFC : 45.85 (+0.09%)
BAC : 39.13 (+0.05%)
TSM : 114.96 (+0.23%)
UNH : 412.34 (-0.09%)
MS : 98.30 (-0.33%)
USB : 57.10 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

3rd Resistance Point 21.77
2nd Resistance Point 21.51
1st Resistance Point 21.10
Last Price 20.68
1st Support Level 20.43
2nd Support Level 20.17
3rd Support Level 19.76

See More

52-Week High 40.14
Fibonacci 61.8% 31.59
Fibonacci 50% 28.95
Fibonacci 38.2% 26.31
Last Price 20.68
52-Week Low 17.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar